| Raul Rodriguez | |
|
403 Se 1st St Delray Beach FL 33483-4540 | |
| (561) 266-8866 | |
| (561) 266-0033 |
| Full Name | Raul Rodriguez |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 403 Se 1st St, Delray Beach, Florida |
| Authorized Official Name and Position | Cathy A Picillo (MEDICAL DIRECTOR) |
| Authorized Official Contact | 5613321176 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Raul Rodriguez 403 Se 1st St Delray Beach FL 33483-4540 Ph: (561) 266-8866 | Raul Rodriguez 403 Se 1st St Delray Beach FL 33483-4540 Ph: (561) 266-8866 |
| NPI Number | 1891067823 |
|---|---|
| Provider Enumeration Date | 02/07/2012 |
| Last Update Date | 10/05/2018 |
| Medicare PECOS PAC ID | 0042477564 |
|---|---|
| Medicare Enrollment ID | O20120210000087 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891067823 | NPI | - | NPPES |
| 007ZQ | Other | FL | FL BC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0802X | Psychiatry & Neurology - Addiction Psychiatry | ME78266 (Florida) | Primary |
| Provider Name | Joseph A Milisitz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104827864 PECOS PAC ID: 3577521269 Enrollment ID: I20041228000660 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Raul J Rodriguez |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1467475913 PECOS PAC ID: 0345407862 Enrollment ID: I20120210000063 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Anthony Gonzalez |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356604243 PECOS PAC ID: 3375791213 Enrollment ID: I20120927000105 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Roberto Carmona |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538563838 PECOS PAC ID: 4284951633 Enrollment ID: I20150323002008 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Kristy L Beams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952829731 PECOS PAC ID: 3274892245 Enrollment ID: I20180119001160 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Maykelyn Felipe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528575925 PECOS PAC ID: 4587925615 Enrollment ID: I20180306000294 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Eva Solange Goode |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1518471614 PECOS PAC ID: 5092077362 Enrollment ID: I20180326002290 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Monika Lanuez |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1558706176 PECOS PAC ID: 6406119437 Enrollment ID: I20180404001834 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Abigail R Biglane |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1568817344 PECOS PAC ID: 2769734235 Enrollment ID: I20181010003427 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Mark A Medlin |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1164459582 PECOS PAC ID: 3274421441 Enrollment ID: I20181101002889 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Aditya Vora |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1750794087 PECOS PAC ID: 4486999174 Enrollment ID: I20181228000431 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Justin Nepa |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1932512118 PECOS PAC ID: 1850637455 Enrollment ID: I20190117002166 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Fonglan Luong |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568978161 PECOS PAC ID: 3779675210 Enrollment ID: I20190124002770 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Clark Hawkins |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1649627886 PECOS PAC ID: 4789926627 Enrollment ID: I20190425000989 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Nicole Iodice |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740717339 PECOS PAC ID: 6204164791 Enrollment ID: I20190821004091 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Melissa Beatrice Barrera |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336780543 PECOS PAC ID: 3274967740 Enrollment ID: I20191217001490 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Brittany Sue Lipinski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811350127 PECOS PAC ID: 6305182767 Enrollment ID: I20200115002402 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Vincent R Kennedy |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1053764662 PECOS PAC ID: 9335575158 Enrollment ID: I20200213002624 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Mohammed Ansari |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1811438682 PECOS PAC ID: 0840627477 Enrollment ID: I20200220002178 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Lori B Kupferman |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1154810216 PECOS PAC ID: 8628140449 Enrollment ID: I20200228000640 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Annaliese Marjorie Thomas |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932416807 PECOS PAC ID: 4981966199 Enrollment ID: I20200522000169 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Skyler Rosen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326601675 PECOS PAC ID: 1658792874 Enrollment ID: I20200526001854 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Guerline Veillard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275179558 PECOS PAC ID: 8022437870 Enrollment ID: I20200929001936 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Nadege Francois |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114563418 PECOS PAC ID: 6204248537 Enrollment ID: I20201210001355 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Kathryn Amanda Kowalczyk |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114415577 PECOS PAC ID: 2264836782 Enrollment ID: I20210805002294 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Manoj Kumar Shukla |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598336802 PECOS PAC ID: 7012313513 Enrollment ID: I20210908004228 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Cara M Harbaugh |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1396470803 PECOS PAC ID: 8325422280 Enrollment ID: I20220826002002 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Kelsey L Reynolds |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1801561188 PECOS PAC ID: 6002291614 Enrollment ID: I20220919001387 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Kristina Elizabeth Encalada |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578286142 PECOS PAC ID: 8325424062 Enrollment ID: I20221003002118 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Seth Watson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659017374 PECOS PAC ID: 8426427055 Enrollment ID: I20221202002984 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Sherril Schwartz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1699425470 PECOS PAC ID: 6305211178 Enrollment ID: I20230410000016 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Erica Lynn Spina |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447938329 PECOS PAC ID: 4183086135 Enrollment ID: I20230808003647 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Nathan J Kadan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336926948 PECOS PAC ID: 1557715182 Enrollment ID: I20230929002027 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Sandra C Cuevas |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780273862 PECOS PAC ID: 3173971157 Enrollment ID: I20231201000526 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Nikki Messer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1851909337 PECOS PAC ID: 6507214459 Enrollment ID: I20231203000130 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
| Provider Name | Matthew Sheridan |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1649973116 PECOS PAC ID: 9335582519 Enrollment ID: I20240205001435 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.
The Asbestos Disease Awareness Organization, combining education, advocacy and community as the largest U.S. organization serving as the voice of asbestos victims, today applauds Senator Max Baucus and cosponsors for introducing a resolution that declares the first week of April as "National Asbestos Awareness Week" and seeks to "raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure."
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.
› Verified 8 days ago
Intervention Strategies, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 297 Ne 6th Ave, Delray Beach, FL 33483 Phone: 561-243-0407 Fax: 561-243-0030 | |
Jacqueline B Pevny Md Pa Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2040 Alta Meadows Ln, Suite 1601, Delray Beach, FL 33444 Phone: 561-272-4888 | |
Carl A Salvati M D P A Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 13455 Military Trl, Suite A, Delray Beach, FL 33484 Phone: 561-495-4644 Fax: 561-495-5191 | |
U Turn Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 206 Sw 13th Ave, Delray Beach, FL 33444 Phone: 954-746-8232 Fax: 954-746-8981 | |
Holistic Home & Health, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15200 Jog Rd, 303, Delray Beach, FL 33446 Phone: 828-237-1238 | |
Boca Palms Medical Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Congress Park Dr, Suite 100, Delray Beach, FL 33445 Phone: 561-361-6608 Fax: 561-361-9857 | |
Brian Gong Psychotherapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 401 Linton Blvd, Suite 200-a, Delray Beach, FL 33444 Phone: 561-501-1008 Fax: 561-431-2608 |